Surgery plus systemic therapy for liver cancer with spread
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining surgery to remove the main liver tumor with systemic therapy (medicines that work throughout the body) can help patients with hepatocellular carcinoma that has spread outside the liver. The goal is to improve outcomes for patients whose primary tumor can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Confirmed hepatocellular carcinoma (liver cancer) by imaging or biopsy
- Primary liver tumor that can be surgically removed with clear margins (R0 resection)
- Good overall health status (ECOG 0–1: able to carry out daily activities with minimal or no limitations)
- At least one measurable cancer spot outside the liver
- Liver function that is stable or only mildly impaired (Child-Pugh class A or stable B7)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.